The antibody is directed against the leukocyte common antigen (L-CA), present on all leukocytes but not erythroid cells or cells from other tissues. The OX-29 competes for binding with OX-1 but recognises half the number of sites.
| Institute |
|---|
| Medical Research Council; University of Oxford |
| SKU: | 156590 |
|---|---|
| Product description: | The antibody is directed against the leukocyte common antigen (L-CA), present on all leukocytes but not erythroid cells or cells from other tissues. The OX-29 competes for binding with OX-1 but recognises half the number of sites. |
| Conjugation: | Unconjugated |
| Immunogen: | Rat lymph node cells and glycoproteins |
| Myeloma used: | NS0/U |
| Cat. #: | 156590 |
|---|---|
| Unit size: | 100 ug |
| Application: | FACS |
| Target: | CD45 |
| Reactivity: | Rat |
| Host: | Mouse |
| Class: | Monoclonal |
| Target background: | The antibody is directed against the leukocyte common antigen (L-CA), present on all leukocytes but not erythroid cells or cells from other tissues. The OX-29 competes for binding with OX-1 but recognises half the number of sites. |
|---|
| Format: | Liquid |
|---|---|
| Shipping conditions: | Dry ice |
| References: |
Woollett et al. 1985. Eur J Immunol. 15(2):168-73. PMID: 2578966. |
|---|
| Cat. # | Tool Name | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 151029 | Anti-HSVICP8 [11E2] |
Key Info
Anti-HSVICP8 [11E2]
|
View Tool | |||||||||||||||||||
| 151020 | Anti-CyclinB1 [V143.1] |
Key Info
Anti-CyclinB1 [V143.1]
|
View Tool | |||||||||||||||||||
| 151030 | Anti-Progesterone [11P14] |
Key Info
Anti-Progesterone [11P14]
|
View Tool | |||||||||||||||||||
| 151035 | Anti-CD8 [14] mAb |
Key Info
Anti-CD8 [14] mAb
|
View Tool | |||||||||||||||||||
| 151038 | Anti-Cytochrome P450 4A2, 4A3 [Clo4] |
Key Info
Anti-Cytochrome P450 4A2, 4A3 [Clo4]
|
View Tool | |||||||||||||||||||
Please note we may take up to three days to respond to your enquiry.
CancerTools.org uses the contact information provided to respond to you about our research tools and service. For more information please review our privacy policy.